Author:
Cennetoğlu Pakize,Öz Zeynep,Caymaz Canan,Perk Yücel Peren,Arıcan Pınar,Kafadar İhsan
Reference19 articles.
1. The ımmune response in multiple sclerosis;Rodríguez Murúa;Annu Rev Pathol,2022
2. 2. de Chalus A, Taveira M, Deiva K. Pediatric onset multiple sclerosis: future challenge for early diagnosis and treatment. Presse Med 2021;50:104069.
3. 3. Waubant E, Banwell B, Wassmer E, et al. Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology 2019;92:e2538-e2549.
4. 4. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010;74(Suppl 1):S17-S24.
5. 5. Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020;77:184-191. Erratum in: JAMA Neurol 2021.